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Summary Human AP endonuclease (HAP1) plays a major role in the repair of apurinic/apyrimidinic (AP) sites in cellular DNA. We used
immunohistochemistry to examine the expression of HAP1 in normal breast and in 102 primary breast carcinomas. In normal breast
epithelium, HAP1 had a uniformly nuclear localization. However, in lactating glandular epithelium, the expression of HAP1 was predominantly
cytoplasmic. In carcinomas, both nuclear and cytoplasmic (44%), cytoplasmic (28%) or nuclear staining (24%) were observed. In four cases
(4%), no HAP1 expression was detected. All patterns of expression for HAP1 were demonstrated for ductal carcinomas in situ (DCIS),
although comedo-type DCIS were usually accompanied by mostly cytoplasmic staining. Similarly, the HAP1 expression in regions of invasive
tumour necrosis was cytoplasmic. Pure nuclear HAP1 expression was significantly correlated with lowangiogenesis (P= 0.007) and negative
lymph node status (P = 0.001). In contrast, cases with cytoplasmic as well as nuclear staining were associated with poor prognostic factors,
such as high angiogenesis (P = 0.03) and node positivity (P = 0.03). The pure nuclear staining may be related to better differentiation, as in
normal breast, and hence better prognostic features, and cytoplasmic staining to a more metabolically active phenotype with high protein
synthesis, as in lactating breast.
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The DNA of all organisms, although inherently stable, is under
constant threat from both endogenous and exogenous factors. The
DNA repair process is offundamental importance for the survival
of all species, and recent studies have established the association
ofdefective DNA repair machinery and cancer (Fishel et al, 1993;
Leach et al, 1993).
One of the most common lesions that arise in cellular DNA is
the apurinic/apyrimidinic (AP) site, which results from the hydro-
lysis of the N-glycosyl bond linking the base to the deoxyribose
moiety. AP sites are considered to be both cytotoxic and muta-
genic, and they have been estimated to occur spontaneously at a
rate of approximately 104 cell-' day-' from the mammalian cell
genome (Loeb et al, 1986). Reactive oxygen species generated
either during normal cellular metabolism or by exogenous agents,
such as ionizing radiation, can increase this high error rate still
further (Hutchinson, 1985; Teoule, 1987).
There are specific DNA repair enzymes that recognize AP sites.
The major human AP endonuclease (HAPI), also known as APE,
APEX or Ref-1, is a 37-kDa protein that shows strong primary
sequence similarity to Escherichia coli exonuclease III protein
(Demple et al, 1991; Robson and Hickson, 1991; Robson et al,
1991; Seki et al, 1991; Xanthoudakis and Curran, 1992). HAPI
rapidly initiates a DNA repair process by introducing DNA strand
breaks on the 5' side ofbaseless sites. The deoxyribose phosphate
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residue is subsequently removed by aphosphodiesterase, followed
by filling in of the nucleotide gap by DNA polymerase and DNA
ligase, which seals the nick and permits the accurate progress of a
DNA replication fork.
Apart from its identification as a DNA repair protein, HAPI has
been shown to regulate the reductive activation of oxidized tran-
scription factors, such as AP-1, Myb, Rel and NF-kB (Curran et al,
1988; Abate et al, 1990; Frame et al, 1991; Xanthoudakis et al,
1992). This reduction-oxidation (redox) activity is dependent on a
cysteine residue located near the DNA binding domain of the
factor and is structurally and functionally distinct from the repair
activity of HAPI (Walker et al, 1993; Xanthoudakis et al, 1994).
Despite the accumulating molecular and biochemical data about
the function of this gene, our knowledge about the distribution of
the protein product in normal and neoplastic tissues is particularly
limited. Duguid et al (1995) have recently examined the immuno-
histochemical expression of HAPI in normal tissues and, besides
the expected nuclear localization, a frequent cytoplasmic expres-
sion for HAP1 was also demonstrated in several cell populations.
This finding was confirmed in our laboratory in a wide range of
normal tissues examined (unpublished data) and in colorectal
adenomas and carcinomas (Kakolyris et al, 1997).
Breast cancer accounts for significant morbidity and mortality
and is characterized by high rates of metastasis and recurrence.
Understanding the pathways of DNA damage and repair may be
helpful in modulating drug and radiation resistance. There is
evidence of high oxidative damage in breast cancer (Malins et al,
1993; Thorgeirsson et al, 1993) and therefore assessment of
this major rate-limiting step in repair of these pathways was
undertaken.
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Table 1 Clinicopathological characteristics of patients and tumours
Median age (range)(years) 55 (28-50)
< 50 years (-) 41
> 50 years (-) 61
Surgical treatment
Lumpectomy
Simple mastectomy
Adjuvant treatment
Chemotherapy (CMT)
Tamoxifen (Tx)
Both
None
Lymph nodes (negative/positive)
Median tumour size (range) (cm)
< 2 cm (-)
> 2 cm (-)
Histology
Ductal
Lobular
Other
Grade (ductal)
11
III
Median ERa (range)
< l0a
> 10a
Median EGFRa (range)
< 20a
> 20a
Median follow-up (range) (months)
Deaths/recurrences
77
25
23
39
6
34
31 out of 71
2.3 (0.3-7)
26
76
83
7
12
9
39
35
18.2 (0-695)
49
53
17.1 (0-710)
43
59
54 (26-74)
18 out of 31
visceral disease or failed endocrine therapy. Patients with isolated
soft-tissue relapse additionally received radiotherapy.
Oestrogen receptor (ER) content was determined using an
ELISA technique (Abbot Laboratories, USA) and epidermal
growth factorreceptor (EGFR) was measured by ligand binding of
['25I]EGF to tumour membranes, as previously reported (Needham
et al, 1988; Horak et al, 1992).
Immunohistochemistry
This was performed on formalin-fixed paraffin-embedded sections
cut onto silane-coated slides. To determine the cellular expression
of HAP1 a standard avidin-biotin-peroxidase complex (ABC)
technique was performed, using an anti-HAPI rabbit polyclonal
antibody (Guedson et al, 1979). Polyclonal anti-HAPl antiserum
(HAPI antibody 13) was obtained from rabbits after six injections
of each of 100 gg of recombinant HAP1 protein (Walker et al,
1993). The antiserum was tested for specificity by Western blot-
ting of whole-cell extracts from human HeLa cells (Kakolyris et
al, submitted). For immunohistochemical detection, HAPI was
used in 1:200 concentration determined after serial dilution.
Before incubation with HAP1, sections were subjected to two
microwave irradiations for 5 min each in a heat-stable glass dish
filled with 10 mm citrate buffer, pH 6.0, for antigen retrieval. All
incubations were performed at room temperature and all washings
between incubations in Tris-buffered saline (TBS). Negative
controls consisted of substitution of the primary antibody with an
irrelevant antibody or preimmune serum. The specificity of the
staining was also confirmed by preincubating the antibody for 1 h
with purified antigen (added in a five fold molar excess). This
resulted in almost complete absorption ofthe antibody and inhibi-
tion ofthe tissue reaction.
afmol mg-' protein.
In the present study, we examined the immunohistochemical
expression of HAPI in normal breast and in breast carcinomas.
Our aim was to demonstrate and describe the pattern ofexpression
and to relate this to otherbiological factors, including nodal status,
oestrogen receptor status, tumour grading and angiogenesis.
MATERIALS AND METHODS
Patients and tumours
Samples of normal breast (n = 21), lactating breast (n = 7) and a
consecutive series of primary breast tumour samples (n = 102)
were obtained from the archives of the Department of Cellular
Pathology at the John Radcliffe Hospital, Oxford. Tumours
represented all stages and grades and were treated by simple
mastectomy or lumpectomy and radiotherapy with axillary node
sampling. All patients had histologically confirmed nodal status.
Tumour grading was performed according to the modified Bloom
and Richardson method (Elston et al, 1987). The characteristics of
the tumours are given in Table 1.
Follow-up for all patients was conducted every 3 months for the
first 18 months and every 6 months for 3 years. Adjuvant radio-
therapy to the ipsilateral axilla was administered in all patients
when histological evidence of nodal metastasis was documented.
Confirmed recurrent disease was treated by endocrine manipula-
tion for soft-tissue or skeletal disease or by chemotherapy for
Assessment of microvessel density and quantitation of
tumour angiogenesis
For immunohistochemical detection of tumour vessels, we used
monoclonal antibody JC70, recognizing CD31, and the alkaline
phosphatase/anti-alkaline phosphatase (APAAP) staining proce-
dure as previously described (Cordell et al, 1984). A 25-point
Chalkley eye piece graticule was used to count vascular hot spots
identified by scanning the tumour at x40-100 by two observers
over a conference microscope. Microvessels were defined as
any immunoreactive endothrelial cell(s) separate from adjacent
microvessels. Vessels within the sclerotic body ofthe tumour were
not included. Counting at x250 magnification (0.155 mm2) was
then performed by rotating the graticule in the eye piece to where
the maximum number ofdots overlay stained vessels. The mean of
the three counts was used in the subsequent analysis, and the
tumours with counts >7 were considered to have high vascularity.
Chalkley counts were determined without knowledge of patient
outcome (Fox et al, 1995).
Statistics
The relationships between the different parameters described
above were examined using chi-square tests. Survival curves were
plotted using the Kaplan-Meiermethod (Kaplan andMeier, 1958),
and statistical differences between life tables were determined
with the log-rank test. The statistical analysis was performed using
the Statapackage release 3.1 (Stata, College Station, Texas, USA).
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Figure 1 HAP1 streptavidin-biotin immunoperoxidase staining. (A) Nuclear staining in normal breast. (B) Lactating breast presenting cytoplasmic staining.
(C) Breast carcinoma with nuclear staining. (D) Breast carcinoma with cytoplasmic staining. (E) Mixed nuclear and cytoplasmic staining in breast carcinoma.
(F) Comedo-type DCIS with cytoplasmic staining
RESULTS
Immunohistochemistry
Positive labelling for HAPI was detected in all normal breast cases
and in the majority ofthebreast carcinomas examined. The staining
was strong and was evident either in the nucleus orin the cytoplasm
or was found present in both locations. Details of the staining
pattern observed in the tissues examined are described below.
HAP1 expression in normal breast
In all 21 cases with normal breast tissue we observed strong nuclear
staining in the luminal epithelium of the breast ducts and lobules
(Figure IA). In seven cases, a weak cytoplasmic localization for
HAP1 was also observed. Myoepithelial cells surrounding normal
acini showed no reaction. A proportion of tissue vessels also
reacted for HAPI, which was nuclear for the endothelial cells and
occasionally weakly cytoplasmic for the vascular smooth muscle
cells. Stromal fibroblasts frequently presented nuclear staining,
while the staining in macrophages, when present, was cytoplasmic.
The epithelium of all seven lactating mammary glands examined
showed immunoreactivity with HAPI, which was predominantly
cytoplasmic and occasionally nuclear (Figure IB).
HAPI expression in breast carcipomas
Carcinomas showed all patterns ofexpression for HAPI. Uniform
nuclear staining was detected in 24 out of 102 (24%) (Figure IC)
cases and cytoplasmic in 29 out of 102 (28%) (Figure ID). Both
nuclear and cytoplasmic staining was observed in 45 out of 102
(44%) cases (Figure lE). In 4 out of 102 (4%) cases, no tissue
reaction was seen in tumour cells, although the other stromal
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Table 2 Chi-squared tests of relationship between nuclear staining and
angiogenesis and lymph node status
Nuclear All othersa Total
Angiogenesisb
Low 23 54 77
High 1 24 25
Total 24 78 102
Lymph node status
cNegative 23 48 71
Positive 1 30 31
Total 24 78 102
aAll others: cytoplasmic, both nuclear and cytoplasmic and negative.
bFisher's exact test P = 0.007. cFisher's exact test P = 0.001.
components showed positivity. A similar pattern of expression to
that demonstrated forcarcinomas was obtained in the in situ ductal
carcinomas (DCIS), when present, in our cases. Hence, nuclear
cytoplasmic or both localizations were seen. Usually the expres-
sion ofHAPI in DCIS was identical to that observed in the nearby
tumour cells, with the exception of comedo-type DCIS, in which
the predominant pattern of expression was cytoplasmic and occa-
sionally nuclear and cytoplasmic Figure IF). In regions oftumour
necrosis, the staining was predominently cytoplasmic. Other
stromal elements presented a similar expression pattern to that
described in normal breast.
Relationship of HAP1 expression to tumour
characteristics and patients' survival
The ranges and medians together with the categories for age,
histology, size, nodal status ER and EGFR used for statistical
analysis are summarized in Table 1. Significant inverse correla-
tions were observed between nuclear HAPI expression and nega-
tive lymph node status (P = 0.001) and between nuclear HAPI
expression and low angiogenesis (P = 0.007) (Table 2). In contrast,
when both cytoplasmic and nuclear staining was present (45
cases), this pattern correlated with nodal positivity (19 out of 45
positive vs 12 out of 57 all other cases, P = 0.03) and high angio-
genesis (16 out of45 high vs 9 out of57 all other cases, P = 0.03).
There was no significant correlation between HAPI expression
and age, tumour size or ER status. There was no significant differ-
ence in relapse-free survival (RFS) or overall survival (OS) for
patients presenting any pattern ofHAPI expression.
DISCUSSION
In the present study, we have examined the immunohistochemical
expression of HAP1 in normal breast, lactating mammary glands,
DCIS and in a large series of 102 breast carcinomas. The observed
differential localization of HAPI in normal and neoplastic breast
tissues suggests a variety ofroles for this bifunctional protein.
In normal breast epithelium the predominant pattern of expres-
sion for HAPI was nuclear, although a weak cytoplasmic staining
was also seen in some cases. However, in lactating mammary
glands, this pattern was different and the usual pattern of
immunoreactivity was cytoplasmic. Whether this cytoplasmic
localization in lactating breast is relevant to the repair or redox
function of HAPI is unclear. Stromal components, such as fibro-
blasts, macrophages and/or endothelial cells, were often positive
for HAP1, each one showing a specific pattern. HAPI has a
nuclear localization signal sequence in the extreme N-terminal
domain of the protein (Barziley and Hickson, unpublished data),
therefore why it is present in the cytoplasm in some cell types and
not others is unclear. However, this cytoplasmic localization has
also been reported for anotherDNArepairenzyme, 06-methylgua-
nine DNA methyltransferase (MGMT), which protects cells
against the mutagenic effect ofalkylating agents (Lee et al, 1993;
Ishibashi et al, 1995). Possibilities for a repair role of HAPI in
mitochondria or a ribosomal function have been proposed as an
interpretation for this cytoplasmic localization (Tomkinson et al,
1988; Wilson et al, 1994; Duguid et al, 1995; Driggers etal, 1996).
In breast carcinomas, both nuclear and cytoplasmic expression
was the common pattern of immunoreactivity. In most cases, this
immunoreactivity was homogeneous within the tumour body.
When focal differences in the HAP1 expression were observed,
these were not necessarily seen at the infiltrating tumour edge,
which is supposed to be the most replicative and metabolically
active compartment. The staining pattern observed in cases of
DCIS was similar to that ofthe nearby infiltrating tumour, with the
exception of comedo-type DCIS. In comedo-type DCIS, most
cases demonstrated cytoplasmic or both nuclear and cytoplasmic
staining as patterns ofexpression. This expression was frequently
different from that of the accompanying infiltrating tumour.
Similarly, in invasive tumours, adjacent to areas of tumour
necrosis, a mostly cytoplasmic staining was also observed. This
cytoplasmic localization of HAP1 in necrotic areas and comedo-
type DCIS may be relevant to differences in relative oxygen
tensions in these tissues. Hypoxia has been shown to induce HAPI
expression (Walker et al, 1994; Yao et al, 1994). Hence, a possible
redox activity of the protein and a role in protection of newly
synthesized transcription factors from oxidative damage while
they are being transported to the nucleus may be relevant to this
cytoplasmic localization ofHAPI in regions besides necrosis.
The statistical analysis revealed a strong correlation between
nuclear localization of HAPI, low angiogenesis and negative
lymph node status. Also, both cytoplasmic and nuclear localiza-
tion was associated with poor prognostic factors, such as high
angiogenesis and nodal positivity. However, although associated
with these features, no relation to prognosis was demonstrated.
Three out of four patients with no detectable HAPI had a very
poor prognosis. Despite the pathologically demonstrated absence
of nodal involvement in all of them, the time to tumour relapse
was 6, 7 and 18 months, respectively, and two of these patients
have died. It is interesting that in all three cases a high angio-
genesis was demonstrated. In contrast, the remaining HAP1-
negative case, which was associated with better prognosis (RFS
74+ months, OS 74+ months), had low angiogenesis.
Variable expression ofa DNA repair enzyme in the nucleus may
be related to the observation of high residual DNA damage from
free radicals in breast cancer. Whether cases with nuclear localiza-
tion differ in sensitivity to drugs and irradiation may be ofinterest
to examine, particularly as we have shown that levels ofHAPI are
related to sensitivity to several DNA-damaging agents (Walker
et al, 1994).
In conclusion, normal breast tissues showed nuclear localization
ofHAP1, which when present in cancer was associated with good
prognostic features. It may be that localization is regulated during
differentiation and hence the association with less aggressive
phenotype. Similarly, in more metabolically active lactating breast
and also more aggressive tumours, the predominant staining was
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cytoplasmic. It will be ofinterest to study this in breast cancer cell
lines and to see ifhormones inducing differentiation, e.g. heregulin
and E2, also change the expression pattern ofHAPI.
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